Video Experimental Relacionado
Updated: Jan 13, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.4K
Neurodegeneración inducida por epilepsia e intervenciones terapéuticas
Samar Kaddoura1, Anjali Banerjee2, Latha Ganti3,4
1Biology, Montverde Academy, Montverde, USA.
Cureus
|January 7, 2026
Resumen
Este estudio analiza la investigación sobre epilepsia y neurodegeneración, identificando términos clave como convulsiones y estrés oxidativo. La creciente investigación sugiere terapias potenciales para prevenir o revertir el daño neuronal en pacientes con epilepsia.
Área de la Ciencia:
- Neurología
- Neurociencia
- Investigación Biomédica
Sus antecedentes:
- La epilepsia se caracteriza por convulsiones recurrentes y está relacionada con la neurodegeneración.
- Comprender la conexión entre la epilepsia y el daño neuronal es crucial para los resultados de los pacientes.
- La investigación existente destaca la asociación entre la actividad convulsiva y el daño cerebral progresivo.
Objetivo del estudio:
- Realizar un análisis bibliométrico de las publicaciones científicas sobre la neurodegeneración inducida por epilepsia.
- Identificar las tendencias de investigación, los contribuyentes clave y los temas emergentes en este campo.
- Explorar intervenciones terapéuticas potenciales para el daño neuronal en la epilepsia.
Principales métodos:
- Análisis bibliométrico de publicaciones de la base de datos Web of Science.
- Recopilación de datos desde 1989 hasta 2025.
- Identificación y análisis de términos clave, patrones de citación y producción investigadora.
Principales resultados:
- Se identificó un total de 662 publicaciones.
- Los términos clave incluyen convulsiones, hipocampo, epileptogénesis y estrés oxidativo.
- Aumento significativo de la actividad investigadora en los últimos años.
Conclusiones:
- El campo de la neurodegeneración inducida por epilepsia se está expandiendo rápidamente.
- La investigación emergente indica vías prometedoras para el desarrollo de terapias.
- Existe un potencial creciente para prevenir o revertir la neurodegeneración en pacientes con epilepsia.
Videos de Conceptos Relacionados
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:14Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K